<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317744</url>
  </required_header>
  <id_info>
    <org_study_id>1409014705</org_study_id>
    <nct_id>NCT02317744</nct_id>
  </id_info>
  <brief_title>Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo</brief_title>
  <official_title>Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of the combination of Naltrexone and Bupropion
      relative to placebo for reducing binge eating in persons with obesity and binge eating
      disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binge Eating Frequency (Categorical)</measure>
    <time_frame>Post-treatment (at 3 months)</time_frame>
    <description>Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency is defined categorically (presence or absence of binge eating).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binge Eating Frequency (Categorical)</measure>
    <time_frame>6 month follow-up (an average of 6 months following treatment)</time_frame>
    <description>Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency is defined categorically (presence or absence of binge eating).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binge Eating Frequency (Continuous)</measure>
    <time_frame>Post-treatment (at 3 months)</time_frame>
    <description>Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binge Eating Frequency (Continuous)</measure>
    <time_frame>6 month follow-up (an average of 6 months following treatment)</time_frame>
    <description>Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Post-treatment (at 3 months)</time_frame>
    <description>BMI is calculated using measured height and weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>6 month follow-up (an average of 6 months following treatment)</time_frame>
    <description>BMI is calculated using measured height and weight.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Naltrexone/ Bupropion combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg naltrexone and 300 mg bupropion per day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pill placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily placebo medication for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and bupropion combination</intervention_name>
    <arm_group_label>Naltrexone/ Bupropion combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pill Placebo</intervention_name>
    <arm_group_label>Pill placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Binge eating disorder (full criteria as described in the American Psychiatric
             Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)

          -  BMI between 30 kg/m2 and 50 kg/m2

          -  Not taking anti-depressant medications

          -  Read English proficiently enough to read study assessments

          -  Available for duration of treatment plus follow-up period

          -  Able to travel to study location (New Haven, CT) for monthly visits

          -  Agree to study procedures

        Exclusion Criteria:

          -  Medical status judged by study physician as contraindication

          -  History of seizures

          -  Past or current anorexia nervosa, bulimia nervosa

          -  Current medications that influence eating/weight

          -  Current substance use disorder or other severe psychiatric disturbance (e.g.,
             suicidality) that requires immediate treatment

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos M Grilo, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>December 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Bupropion hydrochloride, naltrexone hydrochoride drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
